Glucagon-like peptide 1 (GLP-1) in diabetes and aging

被引:5
|
作者
D'Alessio, D [1 ]
机构
[1] Univ Cincinnati, Div Endocrinol, Cincinnati, OH 45267 USA
来源
JOURNAL OF ANTI-AGING MEDICINE | 2000年 / 3卷 / 03期
关键词
D O I
10.1089/rej.1.2000.3.329
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Glucagon-like peptide 1 (GLP-1) is an intestinal hormone that is secreted after meals and augments insulin secretion in response to absorbed glucose. Experiments in animals have demonstrated that GLP-1 is necessary for normal glucose tolerance. GLP-1 is effective in lowering blood glucose levels in persons with diabetes by increasing insulin secretion, and by suppressing glucagon release, delaying gastric emptying, and possibly other mechanisms as well. Recent studies investigating a potential role for decreased GLP-1 secretion in the glucose intolerance of aging have been inconclusive. However, ongoing research on the therapeutic application of GLP-1 is promising, and GLP-1 or GLP-1 receptor agonists may provide a novel means of treating diabetes and glucose intolerance in the future.
引用
收藏
页码:329 / 333
页数:5
相关论文
共 50 条
  • [1] Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
    Nauck, MA
    [J]. HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 852 - 858
  • [2] Glucagon-like peptide 1 (GLP-1)
    Mueller, T. D.
    Finan, B.
    Bloom, S. R.
    D'Alessio, D.
    Drucker, D. J.
    Flatt, P. R.
    Fritsche, A.
    Gribble, F.
    Grill, H. J.
    Habener, J. F.
    Holst, J. J.
    Langhans, W.
    Meier, J. J.
    Nauck, M. A.
    Perez-Tilve, D.
    Pocai, A.
    Reimann, F.
    Sandoval, D. A.
    Schwartz, T. W.
    Seeley, R. J.
    Stemmer, K.
    Tang-Christensen, M.
    Woods, S. C.
    DiMarchi, R. D.
    Tschoep, M. H.
    [J]. MOLECULAR METABOLISM, 2019, 30 : 72 - 130
  • [3] Glucagon-like peptide 1 (GLP-1) and eating
    Gutzwiller, JP
    Degen, L
    Heuss, L
    Beglinger, C
    [J]. PHYSIOLOGY & BEHAVIOR, 2004, 82 (01) : 17 - 19
  • [4] Glucagon-like peptide 1 (GLP-1) and metabolic diseases
    C. M. Rotella
    L. Pala
    E. Mannucci
    [J]. Journal of Endocrinological Investigation, 2005, 28 : 746 - 758
  • [5] Glucagon-like peptide 1(GLP-1) in biology and pathology
    Meier, JJ
    Nauck, MA
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2005, 21 (02) : 91 - 117
  • [6] Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation
    Punjabi, Mukesh
    Arnold, Myrtha
    Geary, Nori
    Langhans, Wolfgang
    Pacheco-Lopez, Gustavo
    [J]. PHYSIOLOGY & BEHAVIOR, 2011, 105 (01) : 71 - 76
  • [7] The role of glucagon-like peptide 1 (GLP-1) in addictive disorders
    Kruse Klausen, Mette
    Thomsen, Morgane
    Wortwein, Gitta
    Fink-Jensen, Anders
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 625 - 641
  • [8] Glucagon-like peptide 1 (GLP-1) analogues and weight loss
    不详
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2020, 105 (07) : 663 - 663
  • [9] Aspiration risk with glucagon-like peptide 1 (GLP-1) agonists
    Marroquin-Harris, M.
    Olesnicky, B.
    [J]. ANAESTHESIA, 2023, 78 (12) : 1524 - 1524
  • [10] The human glucagon-like peptide-1 (GLP-1) receptor
    Dillon, JS
    Wheeler, MB
    Leng, XH
    Ligon, BB
    Boyd, AE
    [J]. PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE ISLETS OF LANGERHANS, 1997, 426 : 113 - 119